Cancer solid tumor

Unlabeled Uses Treafmenf of germ cell cancer, ovarian cancer, pancreatic cancer, renal cell cancer, solid tumors... 

Bladder Cancer Brain Cancer Breast Cancer Cervical Cancer Colon Cancer Head/Neck Cancer Kidney Cancer Leukemia Liver Cancer Lung Cancer Lymphoma Multiple Myeloma Neuroblastoma Ovarian Cancer Pancreatic Cancer Prostate Cancer Sarcoma Skin Cancer Solid Tumors Stomach Cancer Cancer-Related Conditions Other Cancers Unspecified Cancers... 

Lopes de Menezes D E, Mayer L D (2002). Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother. Pharmacol. 49 57-68. 

Observational studies In 24 adult patients with advanced and refractory cancers (solid tumors or lymphomas), the maximum... 

Cancer treatment is a multimodality treatment, i.e., surgery is combined with radiotherapy and antineoplastic chemotherapy. The latter treatment mode is used mainly for cancers which have disseminated. Different forms of cancer differ in their sensitivity to chemotherapy with antineoplastic agents. The most responsive include lymphomas, leukemias, choriocarcinoma and testicular carcinoma, while solid tumors such as colorectal, pancreatic and squamous cell bronchial carcinomas generally show a poor response. The clinical use of antineoplastic agents is characterized by the following principles. 

Storm, G., Roerdink, F. H., Steerenberg, P. A., De jong, W. H., and Crommelin, D. J. A. (1987). Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model, Cancer Res., 47, 3366-3372. 

Many tumors are staged according to the tumor, nodes, metastases (TNM) system. Metastases are cancer cells that have spread to sites distant from the primary tumor site and have started to grow. The most frequently occurring sites of metastasis of solid tumors are the brain, bone, liver, and lungs. 

The usual metastatic sites for solid tumors are the brain, the bone, the lung, and the liver. It is important to realize and educate patients that breast cancer cells may metastasize to the brain, so the individual doesn t have brain and breast cancer but breast cancer metastases to the brain. 

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000 92(3) 205-216. 

H. Maeda and Y. Matsumura, New tactics and basic mechanisms of targeting chemotherapy in solid tumors, in Cancer Chemotherapy Challenge for the Future (K. Kimura. ed.), Excerpta Medical, Tokyo, 1989, p. 42. 

Since the late 1940s, when Farber treated leukemia with methotrexate, cancer therapy with cytotoxic drugs made enormous progress. Chemotherapy is usually integrated with other treatments such as surgery, radiotherapy, and immunotherapy, and it is clear that postsurgery, it is effective with solid tumors. This is due to the fact that only systemic therapy can attack micrometastases. 

Hong FD, Clayman GL. Isolation of a peptide for targeted dmg delivery into human head and neck solid tumors. Cancer Res 2000 60 6551-6556. 

In phase I clinical trials 47 patients, all of whom had previously failed standard treatments for solid tumors, received the drug in the UK, Italy, and Switzerland on three different schedules.123,124 Dose-limiting toxicities have been defined as bone marrow depression and diarrhea. The latter is treatable with loperamide. Signs of biological activity were seen. Notably one patient with metastatic pancreatic cancer showed a partial response (for 4 months) and two further patients, one with metastatic melanoma and one with bronchoalveolar carcinoma, also showed partial responses. In a phase I trial in combination with 5-FU, a partial response in breast cancer was observed.125 Furthermore, a reduction in tumor marker levels was observed in two patients, one with ovarian cancer, and one with colon cancer. Phase II studies have shown partial responses in cisplatin-resistant ovarian and nonsmall-cell lung cancer.126,127 The indications are that the profile of clinical activity is different and complementary to the mononuclear platinum agents. 

Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K (1991) Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res 51 3229-3236... 

Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K (2003) Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63 8977-8983... 

Lung cancer is a solid tumor originating from bronchial epithelial cells. This chapter distinguishes between non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) because they have different natural histories and responses to therapy. 

---